

B2
cont

Cunningham et al., 1996, Cancer Res. 56:4475-4482; Cooney et al., 1996, Cancer Res. 56:4150-4153; Visakorpi et al., 1995, Cancer Res. 55:342-347), indicating a possible role for SSeCKS/Gravin in prostate oncogenesis.

IN THE CLAIMS:

Please amend the claims as follows:

13. (amended) A method of inhibiting cell proliferation in a cell comprising introducing a nucleic acid molecule encoding a SSeCKS polypeptide comprising a CY domain that is capable of binding cyclin D and preventing translocation of cyclin D into the nucleus.

B2

14. (amended) The method of claim 13 wherein the nucleic acid molecule further encodes a cytoskeletal anchoring peptide wherein said peptide is linked to the encoded SSeCKS polypeptide.

15. (amended) A method of inhibiting cell proliferation in a cell comprising introducing a nucleic acid molecule encoding a SSeCKS polypeptide that has an increased affinity for cyclin D as compared to a wild type SSeCKS polypeptide.

REMARKS

Claims 1-12, 21-24 and 27-30 are currently pending. The pending claims are rejected under 35 U.S.C. §112 and §102. For reasons detailed below, the rejections should be withdrawn and the claims allowed to issue. Entry of the foregoing amendments is respectfully requested.